Search
Now showing items 11-20 of 22
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
(
Massachusetts Medical Society
, 2022 , Article)
Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to expedited ...
Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections.
(
Springer
, 2022 , Article)
SARS-CoV-2 breakthrough infections in vaccinated individuals and in those who had a prior infection have been observed globally, but the transmission potential of these infections is unknown. The RT-qPCR cycle threshold ...
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.
(
Massachusetts Medical Society
, 2022 , Article)
The protection conferred by natural immunity, vaccination, and both against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the BA.1 or BA.2 sublineages of the omicron (B.1.1.529) ...
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
(
Elsevier
, 2021 , Article)
Background Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns. SARS-CoV-2 reinfections were assessed in a cohort of antibody-positive persons ...
COVID-19 risk score as a public health tool to guide targeted testing: A demonstration study in Qatar
(
Public Library of Science
, 2022 , Article)
We developed a Coronavirus Disease 2019 (COVID-19) risk score to guide targeted RTPCR testing in Qatar. The Qatar national COVID-19 testing database, encompassing a total of 2,688,232 RT-PCR tests conducted between February ...
Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting
(
NLM (Medline)
, 2021 , Article)
BACKGROUND: Risk of reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. We assessed the risk and incidence rate of documented SARS-CoV-2 reinfection in a cohort of laboratory-confirmed ...
Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study
(
Public Library of Science
, 2021 , Article)
Background The epidemiology of the SARS-CoV-2 B.1.1.7 (or Alpha) variant is insufficiently understood. This study’s objective was to describe the introduction and expansion of this variant in Qatar and to estimate the ...
Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.
(
Oxford University Press
, 2021 , Article)
Strategies for rolling out vaccination against Coronavirus Disease 2019 (Covid-19) varied across countries. A key question is whether delaying administration of the second vaccine dose to vaccinate the largest number of ...
Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant
(
Oxford Academic
, 2021 , Article)
Beta (B.1.351) variant COVID-19 disease was investigated in Qatar. Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for Beta. Odds of progressing to ...
SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar
(
Nature Research
, 2021 , Article)
The SARS-CoV-2 pandemic resulted in considerable morbidity and mortality as well as severe economic and societal disruptions. Despite scientific progress, true infection severity, factoring both diagnosed and undiagnosed ...